Scroll Back to Top
middle aged woman

Breast Cancer 

Labcorp Oncology offers a comprehensive test menu to assist in the diagnosis and management of patients with breast cancer throughout their continuum of care.

supporting image

Genetic Risk Evaluation   |   Diagnostic   |   Prognostic   |   Biomarkers   |   Monitoring   |   Recurrence Risk

DNA icon

Genetic Risk Evaluation

Genetic Risk Testing

BRCAssure® BRCA1/2 Analysis

  • Mutations in BRCA1 and BRCA2 account for the vast majority of families with hereditary breast and ovarian cancer syndrome (HBOC).1
  • 60% to 80% of breast cancers in women with a BRCA1 mutation are triple negative.1
  • The estimated lifetime risk for breast and ovarian cancer is significantly increased in women with BRCA1/2 mutations.1 
  • Both men and women with mutations in BRCA1/2 may also be at increased risk of other cancers, including pancreatic, prostate, and melanoma.2

Learn more about BRCAssure® BRCA1/2 Analysis

Genetic Risk Testing

VistaSeq® Hereditary Cancer Panels

  • VistaSeq Hereditary Cancer Panels provide an assessment of genetic mutations known to be associated with hereditary cancer syndromes.
    • Breast Cancer Panel
    • High/Moderate Risk Breast Cancer Panel
    • Breast and GYN Cancer Panel
  • Genetic tests, like VistaSeq and BRCAssure, inform a patient's risk of cancer and may guide therapy for patients with cancer.
  • Mutation-specific sequencing for patients with a family history of known germline mutations.

Learn more about VistaSeq® Hereditary Cancer Panels

Diagnostic Icon



Complex Tumor Analysis by IHC

Our extensive antibody library and team of pathologists can provide a differential diagnostic analysis in even the most difficult cases.

  • Breast: in situ vs. invasive
  • Breast: ductal vs. lobular
  • TriView Breast (microinvasion) (triple stain CK5/p63/LMW)

Learn more about Complex Tumor Analysis by IHC


Micrometastasis Detection

Detection of metastasis in lymph nodes assists with tumor staging and therapeutic decision making.3

  • Sentinel lymph node analysis by IHC

Learn more about Micrometastasis Detection

Clipboard Icon



p53 by IHC

Marker of aggressiveness of disease. High expression of this marker may indicate a poor prognosis.4

Learn more about p53 by IHC


Ki-67 by IHC

Markers of cell proliferation.5

Learn more about Ki-67 by IHC


PIK3CA Mutation Analysis, Breast Cancer, IVD

PIK3CA mutations are a key driver of breast cancer and have typically been associated with a poor prognosis.6

Learn more about PIK3CA Mutation Analysis, Breast Cancer, IVD

Predictive icon

Biomarkers for Therapeutic Selection 

Biomarkers and tests for clinical management and treatment decision-making

CYP2D6 GenotypeDetects nucleotide variants within the CYP2D6 genetamoxifen7
ER by IHCER protein expressionHormone therapies 7
(FDA approved)
HER2 protein expression or gene amplificationtrastuzumab, pertuzumab, TDM-1, lapatinib7
PD-L1 by IHC
PD-L1 protein expressionpembrolizumab7
PIK3CA Mutation Analysis, Breast Cancer, IVDMutations in the PIK3CA genealpelisib and fulvestrant8
PR by IHCPR protein expressionHormone therapies7
OmniSeq INSIGHT®Includes PD-L1 IHC, DNA and RNA sequencing (523 genes), MSI, TMB*, fusion analysis including NTRK, and immune gene profilingTargeted therapies and immunotherapies
MSI by PCR or Mismatch Repair (MMR) Proteins by IHCMicrosatellite instabilitypembrolizumab7

*TMB - tumor mutational burden

Calendar Icon



CA 27.29 Antigen

For the quantitative determination of CA 27.29 antigen in serum of patients previously treated for stage II or stage III breast cancer.9

Learn more about CA 27.29 Antigen


Recurrence Risk

Recurrence Risk

Prosigna® Breast Prognostic Gene Signature Assay

Prosigna is an FDA 510(k) cleared assay that provides a risk category (low, intermediate, high) and a numerical score (0-100) for the assessment of distant recurrence of disease at 10-years for postmenopausal women with early stage, hormone receptor-positive, invasive breast cancer.10

Learn more about Prosigna® Breast Prognostic Gene Signature Assay